364 related articles for article (PubMed ID: 28277540)
41. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
[TBL] [Abstract][Full Text] [Related]
42. Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication.
Singh S; Vaughan CA; Frum RA; Grossman SR; Deb S; Palit Deb S
J Clin Invest; 2017 May; 127(5):1839-1855. PubMed ID: 28394262
[TBL] [Abstract][Full Text] [Related]
43. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
Dando I; Cordani M; Donadelli M
IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
[TBL] [Abstract][Full Text] [Related]
44. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer.
Schneider-Stock R; Boltze C; Peters B; Szibor R; Landt O; Meyer F; Roessner A
Neoplasia; 2004; 6(5):529-35. PubMed ID: 15548361
[TBL] [Abstract][Full Text] [Related]
45. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.
Kyndi M; Alsner J; Hansen LL; Sørensen FB; Overgaard J
Acta Oncol; 2006; 45(5):602-9. PubMed ID: 16864176
[TBL] [Abstract][Full Text] [Related]
46. Cells with loss-of-heterozygosity after exposure to ionizing radiation in Drosophila are culled by p53-dependent and p53-independent mechanisms.
Brown J; Bush I; Bozon J; Su TT
PLoS Genet; 2020 Oct; 16(10):e1009056. PubMed ID: 33075096
[TBL] [Abstract][Full Text] [Related]
47. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
48. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.
Pourebrahim R; Zhang Y; Liu B; Gao R; Xiong S; Lin PP; McArthur MJ; Ostrowski MC; Lozano G
Genes Dev; 2017 Sep; 31(18):1847-1857. PubMed ID: 29021240
[No Abstract] [Full Text] [Related]
49. Mutant p53: it's not all one and the same.
Kennedy MC; Lowe SW
Cell Death Differ; 2022 May; 29(5):983-987. PubMed ID: 35361963
[TBL] [Abstract][Full Text] [Related]
50. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation.
Kittiniyom K; Mastronardi M; Roemer M; Wells WA; Greenberg ER; Titus-Ernstoff L; Newsham IF
Genes Chromosomes Cancer; 2004 Jul; 40(3):190-203. PubMed ID: 15138999
[TBL] [Abstract][Full Text] [Related]
51. Mutant p53 partners in crime.
Kim MP; Lozano G
Cell Death Differ; 2018 Jan; 25(1):161-168. PubMed ID: 29099488
[TBL] [Abstract][Full Text] [Related]
52. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
Nesslinger NJ; Shi XB; deVere White RW
Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
[TBL] [Abstract][Full Text] [Related]
53. Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblasts.
Agarwal H; Tal P; Goldfinger N; Chattopadhyay E; Malkin D; Rotter V; Attery A
Cell Death Differ; 2024 May; ():. PubMed ID: 38745079
[TBL] [Abstract][Full Text] [Related]
54. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
55. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
Monteith JA; Mellert H; Sammons MA; Kuswanto LA; Sykes SM; Resnick-Silverman L; Manfredi JJ; Berger SL; McMahon SB
Mol Oncol; 2016 Oct; 10(8):1207-20. PubMed ID: 27341992
[TBL] [Abstract][Full Text] [Related]
56. Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis.
Yallowitz AR; Li D; Lobko A; Mott D; Nemajerova A; Marchenko N
Mol Cancer Res; 2015 Apr; 13(4):743-54. PubMed ID: 25573952
[TBL] [Abstract][Full Text] [Related]
57. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
[TBL] [Abstract][Full Text] [Related]
58. Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer.
Marsit CJ; Hasegawa M; Hirao T; Kim DH; Aldape K; Hinds PW; Wiencke JK; Nelson HH; Kelsey KT
Cancer Res; 2004 Dec; 64(23):8702-7. PubMed ID: 15574780
[TBL] [Abstract][Full Text] [Related]
59. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression.
Yue X; Zhang C; Zhao Y; Liu J; Lin AW; Tan VM; Drake JM; Liu L; Boateng MN; Li J; Feng Z; Hu W
Genes Dev; 2017 Aug; 31(16):1641-1654. PubMed ID: 28947497
[TBL] [Abstract][Full Text] [Related]
60. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status.
Mullokandov MR; Kholodilov NG; Atkin NB; Burk RD; Johnson AB; Klinger HP
Cancer Res; 1996 Jan; 56(1):197-205. PubMed ID: 8548763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
